Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01981694 · ClinicalTrials.gov registry record · Phase 1
A Phase I Trial to Investigate the Safety and Tolerability of PF-06649751
A Phase 1 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT01981694 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 18 participants.
The verdict
NCT01981694, a Phase 1 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
This study will determine the safety and tolerability of PF-06649751 given orally to healthy volunteers. To determine the optimal dose for future studies, the concentration of the drug over time will be determined by periodic blood samples. The rate of eye blinks will be measured as an indicator of PF-06649751 action on the receptors of interest in the brain.
Interventions
- DRUG PF-06649751
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2013-11 |
| Est. Completion | 2014-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01981694
The ClinicalTrials.gov registry entry for NCT01981694 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which PF-06649751 is the first listed.
NCT01981694 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01981694 about?
NCT01981694 is a clinical study titled "A Phase I Trial to Investigate the Safety and Tolerability of PF-06649751". This study will determine the safety and tolerability of PF-06649751 given orally to healthy volunteers. To determine the optimal dose for future studies, the concentration of the drug over time will be determined by periodic blood samples. The rate of eye blinks will be measured as an indicator of ...
What is the current status of trial NCT01981694?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2013-11. Estimated completion is 2014-02.
What interventions are being tested in trial NCT01981694?
The interventions under investigation include: PF-06649751 (DRUG).
Who is sponsoring clinical trial NCT01981694?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.